Sectra Pathology vs Tempus Digital Pathology
Sectra's IDS7 provides worklists, reporting and image review across pathology, radiology and genomics, backed by 510(k) clearances K193054 and K232208. It builds no AI. Tempus's diagnostic product is Paige Prostate Detect, authorized by the FDA under De Novo DEN200080 in September 2021 and CE-IVDR marked. It is meant to run on the scanners and viewers Tempus lists. The Predict, breast, GI and PanCancer tools are research use only.
A prostate-heavy reference lab with a compatible scanner goes to Tempus, because Sectra supplies no detection algorithm of its own and its marketplace apps come from other companies. For that lab, Sectra is the weaker pick. Tempus sells enterprise licensing plus per-test fees, and Sectra publishes no price.
A hospital group digitizing slide reading beside its radiology department chooses Sectra and gets one viewer for both kinds of images.
Pathology · Reviewed November 1, 2026
Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
When to pick each one
Sectra Pathology
- IDS7 worklists, reporting and image review
- Digital Pathology Module, 510(k) March 2020 and April 2024
- Pathology and radiology in one viewer
Tempus Digital Pathology
- Prostate Detect authorized by FDA under De Novo
- Prostate Detect also CE-IVDR marked
- Enterprise license plus per-test fees
Score
Each row shows points earned of points available under the published rubric.
Sectra Pathology
33of 100
Tempus Digital Pathology
38of 100
| Dimension | Sectra Pathology | Tempus Digital Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 12 / 12 | -3.6 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Sectra Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Tempus Digital Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price on the Tempus pages. |
Evidence
Sectra Pathology
FDA decisions
K232208 (opens in new tab)510(k)2024-04-16
Sectra Digital Pathology Module (Version 3.3)
K193054 (opens in new tab)510(k)2020-03-31
Sectra Digital Pathology Module
Tempus Digital Pathology
FDA decisions
K241273 (opens in new tab)510(k)2025-01-09
Paige FullFocus
DEN200080 (opens in new tab)De Novo2021-09-21
Paige Prostate Detect
K201005 (opens in new tab)510(k)2020-07-15
Paige FullFocus
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Sectra Pathology | Tempus Digital Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | SE | US |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.